Table 3

PS matching for patients with eGFR decline ≥40% in comparing patients with stable renal function

	Before PS matching		P value*	After PS matching
	Stable renal function	eGFR decline ≥40%		Stable renal function	eGFR decline ≥40%	P value†
	n=2672	n=125		n=625	n=125	P value†
Characteristic
Age	60.09 (11.42)	59.78 (11.21)	0.763	58.92 (11.60)	59.78 (11.21)	0.450
Male gender	1355 (50.7%)	66 (52.8%)	0.648	343 (54.9%)	66 (52.8%)	0.670
Hypertension	1028 (38.5%)	64 (51.2%)	0.004	356 (57.0%)	64 (51.2%)	0.236
Dyslipidemia	1146 (42.9%)	54 (43.2%)	0.945	262 (41.9%)	54 (43.2%)	0.791
A_1c	7.75 (1.46)	8.6 (2.05)	<0.001	8.47 (1.74)	8.6 (2.05)	0.516
BMI	25.95 (4.01)	26.51 (4.77)	0.133	26.6 (4.3)	26.51 (4.77)	0.831
eGFR	94.75 (34.28)	82.48 (55.83)	0.016	86.47 (35.61)	82.48 (55.83)	0.443
Medication
Sulfonylurea	1276 (47.8%)	77 (61.6%)	0.002	371 (59.4%)	77 (61.6%)	0.641
Metformin	1643 (61.5%)	71 (56.8%)	0.293	369 (59.0%)	71 (56.8%)	0.642
Acarbose	240 (9.0%)	24 (19.2%)	<0.001	101 (16.2%)	24 (19.2%)	0.405
Glinide	104 (3.9%)	10 (8.0%)	0.023	43 (6.9%)	10 (8.0%)	0.656
TZD	182 (6.8%)	5 (4.0%)	0.219	24 (3.8%)	5 (4.0%)	0.933
DPP4i	750 (28.1%)	53 (42.4%)	0.001	261 (41.8%)	53 (42.4%)	0.895
Insulin	340 (12.7%)	39 (31.2%)	<0.001	167 (26.7%)	39 (31.2%)	0.306
RAAS blockade‡	1147 (42.9%)	89 (71.2%)	<0.001	446 (71.4%)	89 (71.2%)	0.971
Statin	759 (28.4%)	38 (30.4%)	0.629	195 (31.2%)	38 (30.4%)	0.860
Fibrate	148 (5.5%)	5 (4.0%)	0.46	30 (4.8%)	5 (4.0%)	0.699

*Compare data between patients with stable renal function before PS matching (n=2672) and patients with eGFR decline ≥40% (n=125).
†Compare data between patients with stable renal function by PS matching (n=625) and patients with eGFR decline ≥40% (n=125).
‡RAAS blockade include ACE inhibitor, angiotensin receptor blocker or direct renin inhibitor.
A1c, glycated hemoglobin; BMI, body mass index; DPP4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; PS, propensity score; RAAS, renin–angiotensin–aldosterone system; TZD, thiazolidinedione.